Piramal Pharma Limited

As of June 30, 2026, Piramal Pharma Limited carries a market capitalization of 223.11B, placing it among publicly traded companies globally. Its enterprise value stands at 223.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Piramal Pharma Limited's next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2026, Piramal Pharma Limited has 1.33B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Piramal Pharma Limited trades at an EV/EBITDA multiple of 29.31 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 223.11B versus a market cap of 223.11B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 9.57M in revenue per employee across its workforce of 9,501.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Piramal Pharma Limited recorded 1.59B in income tax expense. The company reported a pretax loss of -1.37B and -2.96B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Piramal Pharma Limited's stock has declined approximately 1.16% over the past 52 weeks. The 50-day moving average sits at 207.30, while the 200-day moving average is 175.83.

Over the twelve months ended June 30, 2026, Piramal Pharma Limited generated 90.95B in revenue and converted that into -2.96B in net income, yielding earnings per share of -2.26. EBITDA reached 7.61B, while operating income came in at 1.06B.

Over the twelve months ended June 30, 2026, Piramal Pharma Limited posted a gross margin of 62.75, reflecting its pricing power and cost economics. The operating margin of 1.17 and net profit margin of -3.26 provide insight into operational efficiency.

Piramal Pharma Limited's most recent stock split took place on August 2, 2023 with a 209:214 split ratio.